| Balance Sheets | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 1,477 | 1,547 | 1,244 | 1,495 |
| Short-term investments | 12,209 | 12,655 | 13,930 | 14,534 |
| Receivables | 56 | NaN | NaN | 0 |
| Prepaid expenses and other current assets | 950 | 848 | 713 | 1,420 |
| Total current assets | 14,692 | 15,050 | 15,887 | 17,449 |
| Operating lease right-of-use asset | 173 | 183 | 193 | 202 |
| Total assets | 14,865 | 15,233 | 16,080 | 17,651 |
| Accounts payable | 252 | 148 | 165 | 276 |
| Accrued expenses | 1,205 | 1,046 | 1,761 | 1,751 |
| Operating lease liability | 44 | 42 | 41 | 39 |
| Total current liabilities | 1,501 | 1,236 | 1,967 | 2,066 |
| Operating lease liability, non-current | 140 | 151 | 163 | 174 |
| Total liabilities | 1,641 | 1,387 | 2,130 | 2,240 |
| Preferred stock, value | NaN | NaN | NaN | 0 |
| Preferred stock, value-Series AConvertible Preferred Stock | NaN | NaN | NaN | 0 |
| Treasury stock, 2,000 shares at cost as of october 31, 2024 | NaN | NaN | NaN | 0 |
| Common stock, par value .01 per share 100,000,000 shares authorized 33,922,776 and 33,013,829 shares issued and outstanding as of april 30, 2026 and october 31, 2025, respectively | 339 | 335 | 330 | 328 |
| Additional paid-in capital | 270,894 | 268,984 | 266,508 | 265,249 |
| Accumulated deficit | -256,758 | -254,242 | -251,677 | -248,982 |
| Total shareholders equity | 14,475 | 15,077 | 15,161 | 16,595 |
| Noncontrolling interest (note 2) | -1,251 | -1,231 | -1,211 | -1,184 |
| Total equity | 13,224 | 13,846 | 13,950 | 15,411 |
| Total liabilities and equity | 14,865 | 15,233 | 16,080 | 17,651 |
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)